The Effect of Selective Serotonin Reuptake Inhibitor (SSRI) Treatment on Affective Symptoms and Fertility Treatment Outcome in Women Undergoing in Vitro Fertilization (IVF)
NCT00989053 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120
Last updated 2009-10-02
Summary
Women undergoing IVF show a high prevalence of depressive and anxiety symptoms. Furthermore, stress has harmful consequences on IVF and pregnancy outcomes. An immunological cascade was suggested to be involved in the process. Treatment in this setting is usually psychotherapy rather than pharmacotherapy, despite reasonable biological evidence suggesting beneficial influence of antidepressant therapy on pregnancy and well-being. Moreover, pharmacotherapy is more available and affordable than psychotherapy in the public health system. The investigators suggest to study the efficacy of antidepressant treatment in women undergoing IVF treatment, presenting with mild mood symptoms. The investigators hypothesize that treatment will result in a greater attenuation of affective symptoms, as well as in higher pregnancy success rates. Furthermore, certain immunological stress-reactive factors, may prove to be the biological mechanism underlying these effects.
Conditions
- Depression
- Anxiety
- In Vitro Fertilization
Interventions
- DRUG
-
escitalopram
10 mg/d for a duration of 8 weeks
- DRUG
-
1 pill per day for 8 weeks
Sponsors & Collaborators
-
Tel-Aviv Sourasky Medical Center
lead OTHER_GOV
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-01-31
- Primary Completion
- 2012-01-31
- Completion
- 2012-01-31
Countries
- Israel
Study Locations
More Related Trials
-
An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder
NCT00358631 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder
NCT00109044 ·Status: COMPLETED ·Phase: PHASE3
-
Combining Medications to Enhance Depression Outcomes
NCT00590863 ·Status: COMPLETED ·Phase: PHASE4
-
Brain Activity Changes and Treatment Response in Depressed People Who Are Receiving Antidepressant Medication
NCT00375843 ·Status: COMPLETED ·Phase: PHASE4
-
Escitalopram as a Mood Stabilizer for Bipolar II Disorder
NCT00156325 ·Status: COMPLETED ·Phase: PHASE2
-
The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder
NCT00107120 ·Status: COMPLETED ·Phase: PHASE3
-
Specific Effects of Escitalopram on Neuroendocrine Response
NCT00150527 ·Status: COMPLETED
-
A Safety and Efficacy Study of Escitalopram on Acute Treatment of Severe Depression
NCT01814085 ·Status: COMPLETED ·Phase: PHASE4
-
Effects Of Antidepressants On Sexual Functioning In Adults
NCT00051272 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of SSRIs on Response to Psilocybin Therapy
NCT05594667 ·Status: WITHDRAWN ·Phase: PHASE2
-
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
NCT00252356 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects
NCT05175430 ·Status: COMPLETED ·Phase: PHASE1
-
Augmenting Antidepressant Treatment With Interpersonal Psychotherapy for Treating Late-life Depression
NCT00177294 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder
NCT00432614 ·Status: COMPLETED ·Phase: PHASE3
-
Mechanisms of Antidepressant Non-Response in Late-Life Depression
NCT01931202 ·Status: COMPLETED ·Phase: NA
-
Investigating the Protective Impact of LY-2940094 on Stress-induced Depression- and Anxiety-related Phenotypes in Humans
NCT06786637 ·Status: WITHDRAWN ·Phase: PHASE2
-
The Effects of Increased Central Serotonergic Activity on Information Processing
NCT00206934 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression
NCT00200902 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents With Anxiety and Depression
NCT06853587 ·Status: RECRUITING ·Phase: NA
-
Efficacy and Safety of Escitalopram Doses up to 50mg in Treatment of MDD
NCT00785434 ·Status: COMPLETED ·Phase: PHASE4
-
Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment
NCT00352885 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Antidepressants on Sexual Functioning
NCT00051259 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
NCT00252330 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of SSRIs on Threat of Shock Potentiated Neural Circuitry
NCT07074652 ·Status: COMPLETED ·Phase: NA
-
The Effect of Ketamine on Mechanises Underlying Suicidal Ideation and Drug-resistant Major Depression
NCT02037503 ·Status: UNKNOWN ·Phase: PHASE3